BLUE Stock Overview
A biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
bluebird bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.25 |
| 52 Week High | US$28.60 |
| 52 Week Low | US$3.56 |
| Beta | 0.82 |
| 1 Month Change | 28.68% |
| 3 Month Change | -37.05% |
| 1 Year Change | -78.31% |
| 3 Year Change | -94.78% |
| 5 Year Change | -99.38% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%
Jan 04
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
Nov 15bluebird bio: Scientific Success And Financial Success, And The Gap Between
Sep 26bluebird bio's Flight Through Financial Fog And Fierce Rivals
Jun 27bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12Shareholder Returns
| BLUE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 36.4% | -6.4% | -3.0% |
| 1Y | -78.3% | -11.7% | 7.5% |
Return vs Industry: BLUE underperformed the US Biotechs industry which returned -11.9% over the past year.
Return vs Market: BLUE underperformed the US Market which returned 6.1% over the past year.
Price Volatility
| BLUE volatility | |
|---|---|
| BLUE Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BLUE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLUE's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 248 | Andrew Obenshain | www.bluebirdbio.com |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
| BLUE fundamental statistics | |
|---|---|
| Market cap | US$47.78m |
| Earnings (TTM) | -US$240.71m |
| Revenue (TTM) | US$83.81m |
0.6x
P/S Ratio-0.2x
P/E RatioIs BLUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLUE income statement (TTM) | |
|---|---|
| Revenue | US$83.81m |
| Cost of Revenue | US$89.38m |
| Gross Profit | -US$5.57m |
| Other Expenses | US$235.14m |
| Earnings | -US$240.71m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.59 |
| Gross Margin | -6.65% |
| Net Profit Margin | -287.23% |
| Debt/Equity Ratio | -276.4% |
How did BLUE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/01 05:22 |
| End of Day Share Price | 2025/04/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
bluebird bio, Inc. is covered by 33 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Zhiqiang Shu | Berenberg |